TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026)
TherapeuticsMD's (TXMD) quarterly Income from Non-Controlling Interests came in at $517000.0 in Q1 2026, up 26.1% YoY from $410000.0 in Q1 2025, and down 1.9% on a QoQ basis from $527000.0 in Q4 2025.
TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 3 years of Income from Non-Controlling Interests data on file, last reported at $517000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 26.1% year-over-year to $517000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 42.94% YoY) and the FY2025 annual result came in at $1.8 million, up 36.61% from the prior year.
- Income from Non-Controlling Interests fell to $517000.0 in Q1 2026, from $527000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $534000.0 in Q3 2025 to a low of $275000.0 in Q3 2024.
- A 3-year average of $415125.0 and a median of $393000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 94.18% in 2025, down 7.74% in 2025.
- Tracing TXMD's Income from Non-Controlling Interests over 3 years: stood at $333000.0 in 2024, then surged by 58.26% to $527000.0 in 2025, then declined by 1.9% to $517000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $517000.0 (Q1 2026), $527000.0 (Q4 2025), and $534000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | TherapeuticsMD | 23.56 Mn | 14.37 Mn | - | 523,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 523,000.00 |
| Mar 31, 2026 | 517,000.00 |
| Dec 31, 2025 | 527,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 410,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 349,000.00 |